Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that
may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted a …

Objective. To evaluate efficacy and safety, baricitinib [Janus kinase (JAK) 1/JAK2 inhibitor]
was compared with placebo in Japanese patients with active rheumatoid arthritis (RA) despite …

Background: The severe asthma and severe, uncontrolled asthma (SUA) populations in
Japan are not well-studied. We investigated the prevalence of continuously treated severe …

Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by
estimated radiographic progression rate before baseline (BL) in patients with rheumatoid …

Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL)
efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate …

Fig. 5 LS mean CFB in mTSS among patients with any of the PPFs or four PPFs at A W24 or
B W52. Each of the PPF subgroups [sero (?), hsCRP C 6, DAS28 (CRP)[5.1, and erosion [0] …

Introduction Our aim was to evaluate protein biomarker changes related to the administration
of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to …

Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA)
and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 …

Background Patients (pts) with rheumatoid arthritis (RA) and poor prognostic factors 1 (PPF)
are at risk for progression without adequate treatment. Filgotinib (FIL) is a once daily Janus …

Correction: Rheumatol Ther(2023) 10: 1335–1348 https://doi. org/10.1007/s40744-023-00583-9
In the sentence beginning ‘Poster prevented…’under section ‘Prior Presentation’in this …